Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 4Phase 1/2 3Phase NA 1

Status

Unknown 3Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Nasopharyngeal Carcinoma 20Carcinoma, Non-Small-Cell Lung 18Esophageal Squamous Cell Carcinoma 15Breast Neoplasms 14Triple Negative Breast Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Carcinoma, Hepatocellular 11Stomach Neoplasms 8Small Cell Lung Carcinoma 8Uterine Cervical Neoplasms 6Recurrence 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 4Sarcoma 4Rectal Neoplasms 4Neoplasm Metastasis 4Melanoma 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Locally Advanced Rectal Cancer 3Liver Neoplasms 3Turcot syndrome 2Pathologic Complete Response 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Neoplasms 2

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × toripalimab × Clear all
NCT05031494 2025-01-06

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

Eucure (Beijing) Biopharma Co., Ltd

Phase 2 Completed
40 enrolled
Dermatologic

Melanoma

NCT04879654 2024-03-05

SNMM

Eye & ENT Hospital of Fudan University

Phase 2 Unknown
45 enrolled
Dermatologic

Melanoma

NCT05907512 2023-06-22

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Fudan University

Phase 2 Unknown
43 enrolled
Dermatologic

Melanoma

NCT04884997 2021-05-13

A Study of Toripalimab or Combining With Temozolomide(iv) in the Treatment of Advanced/Metastatic Malignant Melanoma

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
90 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡